Department of Pediatric Neurology Rehabilitation Center, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Aug 15;23(8):786-790. doi: 10.7499/j.issn.1008-8830.2106042.
To study the clinical effect of mouse nerve growth factor (mNGF) in the treatment of children with global developmental delay (GDD).
A prospective clinical trial was conducted in 60 children with GDD who were treated in the First Affiliated Hospital of Anhui Medical University between July 2016 and July 2017. These children were randomly divided into two groups: conventional rehabilitation treatment and mNGF treatment group (=30 each). The children in the conventional rehabilitation treatment group were given neurodevelopmental therapy, and those in the mNGF treatment group were given mNGF treatment in addition to the treatment in the control group. The evaluation results of the Gesell Developmental Scale were compared between the two groups before and after treatment.
Before treatment and after 1.5 months of treatment, there was no significant difference in the developmental quotient (DQ) of each functional area of the Gesell Developmental Scale between the mNGF treatment and conventional rehabilitation treatment groups (>0.05). After 3 months of treatment, the mNGF treatment group had significantly higher DQs of gross motor, fine motor, and personal-social interaction than the conventional rehabilitation treatment group (˂0.05). The incidence rate of transient injection site pain after injection of mNGF was 7% (2/30), and there was no epilepsy or other serious adverse reactions.
In children with GDD, routine rehabilitation training combined with mNGF therapy can significantly improve their cognitive, motor, and social abilities.
研究鼠神经生长因子（mNGF）治疗儿童全面发育迟缓（GDD）的临床效果。
前瞻性临床研究纳入 2016 年 7 月至 2017 年 7 月在安徽医科大学第一附属医院就诊的 60 例 GDD 患儿，采用随机数字表法分为常规康复治疗组和 mNGF 治疗组，每组 30 例。常规康复治疗组患儿给予神经发育疗法，mNGF 治疗组在常规康复治疗组基础上加用 mNGF 治疗。比较两组患儿治疗前后的 Gessell 发育量表评估结果。
治疗前及治疗 1.5 个月时，mNGF 治疗组与常规康复治疗组患儿 Gessell 发育量表各能区发育商（DQ）比较，差异均无统计学意义（均>0.05）；治疗 3 个月时，mNGF 治疗组患儿粗大运动、精细运动、个人-社交交往 DQ 均显著高于常规康复治疗组（均<0.05）。mNGF 注射后一过性注射部位疼痛发生率为 7%（2/30），未发生癫痫等严重不良反应。
常规康复训练联合 mNGF 治疗可显著改善 GDD 患儿的认知、运动和社会能力。
